Relay Therapeutics, Inc.
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- Relay Therapeutics, Inc.
- Company name
- Relay Therapeutics, Inc.
- Organisation type
- Industry
- Registered legal name
- Relay Therapeutics, Inc.
- US industry code (SIC)
- Biological products, (no disgnostic substances)
- Registry sponsor category
- Industry
- SEC filer number (CIK)
- 0001812364
Related records
Trials (6)
- A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
- A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
- A Study to Assess Virtual Reality by Healthcare Providers: A Pilot Study
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
- Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer